Overview
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-07-20. Active
11 1090 2590 0000 0001 4684 4704- 34 1090 2590 0000 0001 4486 8982
- 84 1090 2590 0000 0001 4486 8470
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
5 public aid cases recorded, with a total value of $5,532,661.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 14, 2025 | Aid for research and development projects: industrial research | $2.5M$2,456,182 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jan 14, 2025 | Aid for research and development projects: experimental development | $449.5K$449,461 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jan 14, 2025 | Aid for SMEs for innovation support | $15,068$15,068 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-01-01 | Rozwój innowacyjnego inhibitora metaloproteinaz MMP jako pierwszego w swojej klasie leku modyfikującego przebieg MMVD i SAS u psów. | $3.7M$3,728,386 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2020-04-01 | Prace przedkliniczne i badania kliniczne I fazy innowacyjnego kandydata na lek w niewydolności serca typu HFpEF | $2.6M$2,611,950 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, that member of the management board makes declarations of will on behalf of the company. In the case of a management board consisting of two or more persons, two members of the management board acting jointly or a member of the management board acting jointly with a commercial proxy are authorised to make declarations of will on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Vasa Therapeutics, Inc. | 189 | $2,552.67 | 100% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Adam Kruszewski (61)  | Osoba fizyczna sprawująca kontrolę nad spółką orphinic scientific s.a. jako akcjonariusz, któremu przysługuje prawo własności więcej niż 25% ogólnej liczby akcji tej spółki, która to spółka jest udziałowcem spółki zagranicznej vasa therapeutics, inc. posiadającym więcej niż 25% ogólnej liczby udziałów ww. spółki zagranicznej. spółce vasa therapeutics, inc. przysługuje więcej niż 25% ogólnej liczby udziałów w spółce vasa therapeutics sp. z o.o. |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Wstechnologysp. z o.o. | $258,318.71 | wstechnology.pl | ||
| Centrum Badań Weterynaryjnych Vetcomplexsp. z o.o. | $255,522.81 | vetcomplex.pl | ||
| Vitrotest Europesp. z o.o. | $233,350.77 | vitrotest.pl | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| Phage Consultantssp. z o.o. | $193,130.82 | phageconsultants.com | ||
| Bactremsp. z o.o. | $181,958.36 | bactrem.pl | ||
| MultiqureS.A. | $149,394.35 | purebiologics.com | ||
| GenomtecS.A. | $54,746.36 | genomtec.com | ||
| Centrum Transferu Technologii Meditransfer Iitdsp. z o.o. | $228.56 | iitd.pan.wroc.pl | ||
| Olenasp. z o.o. | — | imsolutions.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-12-02 | Address change (Ul. Duńska 9/D009, 54-427, Wrocław → Ul. Duńska 9/2/23, 54-427, Wrocław) | |
| 2025-12-02 | Share capital change (9,150.00 PLN → 9,450.00 PLN) | |
| 2024-10-23 | Share capital change (8,350.00 PLN → 9,150.00 PLN) | |
| 2024-07-25 | Share capital change (7,350.00 PLN → 8,350.00 PLN) | |
| 2024-02-22 | Share capital change (6,350.00 PLN → 7,350.00 PLN) |
FAQ
Last updated: 2026-07-04